Last mentioned: Jun 14, 2026
Across the most recent 1 story covering Rusfertide — 100% neutral sentiment, averaging 6/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
This page surfaces every story mentioning Rusfertide across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Rusfertide was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |